Anti-CRISPR-mediated continuous directed evolution of CRISPR-Cas9 in human cells

Abstract

Engineering CRISPR-Cas systems for improved or altered function is central to both research and therapeutic applications. Unfortunately most optimization, especially directed evolution in bacterial hosts, fails to capture the functional requirements of the complex mammalian cellular milieu, where activity is usually required. Robust strategies to enable continuous directed evolution of genome-targeting agents directly in human cells remain lacking. Here, we introduce CRISPR-MACE (Mammalian cell-enabled Adenovirus-assisted Continuous Evolution) as a foundational technology to address this need. CRISPR-MACE integrates virus-based continuous evolution with anti-CRISPR-based tunable selection to generate novel Streptococcus pyogenes Cas9 variants with both increased and decreased DNA binding capacity and nearly 1000-fold-enhanced resistance to AcrIIA4, the strongest known inhibitor of SpCas9. Notably, across independent evolution campaigns the same Cas9 gatekeeper mutation reproducibly emerged first, enabling subsequent adaptive steps along two interdependent axes of Cas9 function. In addition to advancing CRISPR technologies, this work establishes key principles and synthetic circuits for continuously evolving CRISPR-Cas systems directly in human cells. SIGNIFICANCE STATEMENTCRISPR technologies are typically engineered in bacteria, even though they must function in the far more complex environment of human cells. This gap has limited the discovery of variants with improved DNA recognition or with resistance to inhibitors that operate differently in mammalian systems. Here we establish CRISPR-MACE, a continuous evolution platform that leverages pressure from anti-CRISPR proteins to select Cas9 variants directly in human cells that have novel functions. Evolved variants show improvements in DNA binding strength and residence time, as well as striking escape from the potent Cas9 inhibitor AcrIIA4. Many anti-CRISPR proteins use distinct mechanisms, so our strategy can drive future continuous evolution campaigns in mammalian cells that expand the functional properties of genome-targeting agents.